MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra ...

Rare disease research is vital to improve the lives of hundreds of millions of people worldwide. However, small target populations, combined with increasing drug development costs, can deter ...

Department of Theoretical Biophysics, Max Planck Institute of Biophysics, Max-von-Laue Straße 3, 60438 Frankfurt am Main, Germany Institute for Biophysics, Goethe University Frankfurt, 60438 Frankfurt ...

Discovered in 1931 by Harold Clayton Urey, and soon after already awarded by the Nobel Prize in Chemistry in 1934, deuterium is a stable and nonradioactive isotope of hydrogen differing only by an ...